NEW YORK (GenomeWeb) – Biodesix said today that it has acquired Seattle-based Integrated Diagnostics.
Financial terms of the deal were not disclosed.
The acquisition adds Indi's XL2 lung cancer test to Biodesix's portfolio. A second generation technology of what was previously called Xpresys Lung, the XL2 test measures two protein markers in the blood, which, combined with other pathologic and clinical factors, can improve the identification of cancers in individuals who have had a lung nodule detected via imaging.
The assay is designed to help reduce unnecessary biopsies by helping to rule out those who have a low risk of malignancy based on their XL2 biomarker status.
According to Biodesix, XL2 is a good complement to its existing lung cancer assays, which include the proteomic VeriStrat prognostic assay, and the GeneStrat liquid biopsy test, which noninvasively detects actionable mutations in advanced lung cancer patients.
"Adding XL2 to our portfolio demonstrates our commitment to helping physicians and patients battle lung disease across a continuum of clinical presentations," Biodesix CEO David Brunel said in a statement.
Indi had struggled in years past to gain adoption of the XL2 test's predecessor, and CEO Al Luderer added that his firm has been "actively exploring" the optimal path to bring the second-generation test to the market. "[W]e are impressed by Biodesix's rapidly expanding commercial presence and extensive lung disease product pipeline,” he said.